NCT06465108: An ongoing trial by MBX Biosciences
This trial is ongoing. It must report results 5 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06465108 |
|---|---|
| Title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of MBX 2109 in Patients With Hypoparathyroidism (Avail Study) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 8, 2024 |
| Completion date | May 23, 2025 |
| Required reporting date | May 23, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |